Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

LAVA Therapeutics Q4 EPS $(0.24) Misses $(0.12) Estimate, Sales $353.00K Miss $6.25M Estimate

Author: Benzinga Newsdesk | March 20, 2024 07:13am
LAVA Therapeutics (NASDAQ:LVTX) reported quarterly losses of $(0.24) per share which missed the analyst consensus estimate of $(0.12) by 100 percent. This is a 57.89 percent increase over losses of $(0.57) per share from the same period last year. The company reported quarterly sales of $353.00 thousand which missed the analyst consensus estimate of $6.25 million by 94.35 percent. This is a 86.63 percent decrease over sales of $2.64 million the same period last year.

Posted In: LVTX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist